Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
| Conditions: | Mesothelioma |
| Start Date: | December 1, 2002 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00061477 |
| Study Type: | Interventional |
| Intervention: | Drug: Pemetrexed|Drug: Gemcitabine |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Eli Lilly and Company |
| Ages: | Adult|Senior |
| Enrollment: | 48 |
| Funded By: | Industry |
| First Received: | May 28, 2003 |
| End Date: | September 1, 2006 |
| Last Updated: | January 24, 2007 |
| Last Verified: | January 1, 2007 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
